Hana Müllerova
- Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohortBy Alvar Agusti, Lisa D. Edwards, Bartolomé Celli, William MacNee, Peter M. A. Calverley, Hana Müllerova, David A. Lomas, Emiel Wouters, Per Bakke, Steve Rennard, Courtney Crim, Bruce E. Miller, Harvey O. Coxson, Julie C. Yates, Ruth Tal-Singer and Jørgen VestboAlvar Agusti1Thorax Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona and CIBER Enfermedades Respiratorias, FISIB, Mallorca, SpainLisa D. Edwards2GlaxoSmithKline, Research Triangle Park, NCBartolomé Celli3Dept of Respiratory Medicine; Brigham and Women's Hospital, Boston, MAWilliam MacNee4University of Edinburgh & Royal Infirmary, EdinburghPeter M. A. Calverley5Dept of Respiratory Medicine, University Hospital Aintree, LiverpoolHana Müllerova6Epidemiology, GlaxoSmithKline R&D, MiddlesexDavid A. Lomas7Dept of Medicine, University of Cambridge, Cambridge Institute for Medical Research, CambridgeEmiel Wouters8Dept of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The NetherlandsPer Bakke9Institute of Medicine, University of Bergen, Bergen10Dept of Thoracic Medicine, Haukeland University Hospital, Bergen, NorwaySteve Rennard11University of Nebraska Medical Center, Omaha, NECourtney Crim2GlaxoSmithKline, Research Triangle Park, NCBruce E. Miller12GlaxoSmithKline, King of Prussia, PA, USAHarvey O. Coxson13Dept of Radiology, University of British Columbia, Vancouver General Hospital, Vancouver, BC, CanadaJulie C. Yates2GlaxoSmithKline, Research Triangle Park, NCRuth Tal-Singer12GlaxoSmithKline, King of Prussia, PA, USAJørgen Vestbo14Dept of Respiratory Medicine, Odense University Hospital/University of Southern Denmark, Denmark15Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK
- BMI and risk for death in COPDBy Berne Eriksson, Eva Rönmark, Anne Lindberg, Hana Müllerova and Bo LundbäckBerne ErikssonEva RönmarkAnne LindbergHana Müllerova4World Wide Epidemiology, GlaxoSmithKline, Greenford, United Kingdom
- Fatigue components in COPD patients and controls using the FACIT-F scale; data from ECLIPSE studyBy Khaled Al-Shair, Hana Müllerova, Nicholas Locantore, Nicola Hanania, Amir Sharafkhaneh, Emiel Wouters, Stephen Rennard and Jørgen VestboKhaled Al-Shair1Medicines Evaluation Unit/North West Lung Research Centre, Manchester University, South Manchester University Hospital, Manchester, United KingdomHana Müllerova2Worldwide Epidemiology, GlaxoSmithKline R&D at Stockley Park, Uxbridge, United KingdomNicholas Locantore3Respiratory and Inflammation Medicines Development Center, GlaxoSmithKline R&D at Research Triangle Park, NC, United StatesNicola Hanania4Section of Pulmonary and Critical Medicine, Baylor College of Medicine, Houston, TX, United StatesAmir Sharafkhaneh5Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, United StatesEmiel Wouters6Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, NetherlandsStephen Rennard7University of Nebraska Medical Center, University of Nebraska, Omaha, United States
- Dyspnoea in COPD patients recorded in a primary care databaseBy Hana Mullerova, Chao Lu and Maggie TabbererHana Mullerova1Worldwide Epidemiology, Quantitative Sciences, GlaxoSmithKline R&D, Uxbridge, United KingdomChao Lu1Worldwide Epidemiology, Quantitative Sciences, GlaxoSmithKline R&D, Uxbridge, United KingdomMaggie Tabberer2Global Health Outcomes, GlaxoSmithKline R&D, Uxbridge, United Kingdom
- Fatigue in COPD and the impact of heart disease comorbidity: A population-based studyBy Caroline Stridsman, Hana Müllerova, Lisa Skär and Anne LindbergCaroline StridsmanHana Müllerova3WorldWide Epidemiology, GlaxoSmithKline R&D, Stockley Park, United KingdomLisa Skär1Department of Health Science, Division of Nursing, Luleå University of Technology, Luleå, Sweden
- GOLD assessment of COPD patients: Impact of symptoms assessment choiceBy Hana Mullerova, Nicholas Locantore and Paul JonesHana Mullerova1Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, United KingdomNicholas Locantore2Clinical Statistics, GlaxoSmithKline R&D, Research Triangle Park, NC, United StatesPaul Jones3Clinical Science, St. George's University, London, United Kingdom
- Profiling dyspnoea in primary care patients with COPDBy Hana Mullerova, Chao Lu and Maggie TabbererHana Mullerova1Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, United KingdomChao Lu2Worldwide Epidemiology, GlaxoSmithKline R&D, Research Triangle Park, NC, United StatesMaggie Tabberer3Global Health Outcomes, GlaxoSmithKline R&D, Uxbridge, United Kingdom
- The relationship between persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohortBy Daisy Janssen, Alvar Agusti, Hana Müllerova, Julie Yates, Ruth Tal-Singer, Stephen Rennard, Jorgen Vestbo and Emiel WoutersDaisy Janssen1Program Development Centre, CIRO+, Center of Expertise for Chronic Organ Failure, Horn, NetherlandsAlvar Agusti2Thorax Institute, IDIBAPS, University of Barcelona, Barcelona, SpainHana Müllerova3Respiratory and Inflammation Medicines Development Center and Worldwide Epidemiology, GlaxoSmithKline, Uxbridge, United KingdomJulie Yates3Respiratory and Inflammation Medicines Development Center and Worldwide Epidemiology, GlaxoSmithKline, Uxbridge, United Kingdom4Research Triangle Park, GlaxoSmithKline, NC, United StatesRuth Tal-Singer5Respiratory Therapy Area Unit, GlaxoSmithKline, Pennsylvania, United StatesStephen Rennard6Pulmonary and Critical Care Medicine Section, University of Nebraska Medical Centre, Nebraska, United StatesJorgen Vestbo7Department of Cardiology and Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Hvidovre, DenmarkEmiel Wouters1Program Development Centre, CIRO+, Center of Expertise for Chronic Organ Failure, Horn, Netherlands8Respiratory Medicine, Maastricht UMC+, Maastricht, Netherlands
- Factors associated with COPD exacerbation frequency in a UK primary care cohortBy Hana Müllerová, Amit Shukla, Adam Hawkins and Jennifer QuintHana Müllerová1Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, United KingdomAmit Shukla2Worldwide Epidemiology, GlaxoSmithKline R&D, Upper Providence, United StatesAdam Hawkins3Medical Affairs, GlaxoSmithKline UK Pharma, Uxbridge, United KingdomJennifer Quint4Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom
- Characteristics, stability and outcomes of the gold 2011 copd groups in the eclipse cohortBy Alvar Agusti, Lisa D. Edwards, Bartolomé Celli, William MacNee, Peter M. A. Calverley, Hana Mullerova, David A. Lomas, Emiel Wouters, Per Bakke, Steve Rennard, Courtney Crim, Bruce E. Miller, Harvey O. Coxson, Julie C. Yates, Ruth Tal-Singer, Jørgen Vestbo and for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators (see Appendix)Article | Published in 2013 in European Respiratory JournalAlvar Agusti*Thorax Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona and CIBER Enfermedades Respiratorias, FISIB, Mallorca, SpainLisa D. Edwards#GlaxoSmithKline, Research Triangle Park, NC, USABartolomé Celli¶Dept of Respiratory Medicine; Brigham and Women's Hospital, Boston, MA, USAWilliam MacNee+University of Edinburgh & Royal Infirmary, Edinburgh, UKPeter M. A. Calverley§Dept of Respiratory Medicine; University Hospital Aintree, Liverpool, UKHana MullerovafEpidemiology, GlaxoSmithKline R&D, Stockley Park, Middlesex, UKDavid A. Lomas**Dept of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UKEmiel Wouters##Dept of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, the NetherlandsPer Bakke¶¶Institute of Medicine, University of Bergen, and Dept of Thoracic Medicine, Haukeland University Hospital, Bergen, NorwaySteve Rennard++University of Nebraska Medical Center, Omaha, NE, USACourtney Crim#GlaxoSmithKline, Research Triangle Park, NC, USABruce E. Miller§§GlaxoSmithKline, King of Prussia, PA, USAHarvey O. CoxsonffDept of Radiology, University of British Columbia, Vancouver General Hospital, Vancouver, BC, CanadaJulie C. Yates#GlaxoSmithKline, Research Triangle Park, NC, USARuth Tal-Singer§§GlaxoSmithKline, King of Prussia, PA, USAJørgen Vestbo***Dept of Respiratory Medicine, Odense University Hospital/University of Southern Denmark, Denmark, and University of Manchester, Manchester Academic Health Sciences Centre, UK
- One-year change in health status and outcomes in chronic obstructive pulmonary diseaseBy Sarah Wilke, Paul Jones, Hana Müllerova, Nicholas Locantore, Jorgen Vestbo, Ruth Tal-Singer, Frits Franssen, Alvar Agusti, Per Bakke, Peter Calverley, Harvey Coxson, Courtney Crim, Lisa Edwards, David Lomas, William MacNee, Stephan Rennard, Julie Yates, Emiel Wouters and Martijn SpruitSarah Wilke1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsPaul Jones2Division of Clinical Science, St. George’s University of London, London, United KingdomHana Müllerova3Respiratory Epidemiology, GlaxoSmithKline, Uxbridge, United KingdomNicholas Locantore4GlaxoSmithKline, Research Triangle Park, North Carolina,Jorgen Vestbo5Department of Respiratory Medicine, Odense University Hospital, Clinical Institute, University of Southern Denmark, Odense, Denmark6Respiratory Research Group, Manchester Academic Health Sciences Centre, University Hospital South Manchester NHS Foundation, Manchester, United KingdomRuth Tal-Singer7GlaxoSmithKline, GlaxoSmithKline Research and Development, King of Prussia,Frits Franssen1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsAlvar Agusti8Thorax Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona and CIBER Enfermedades Respiratorias (CIBERES), Barcelona, SpainPer Bakke9Department of Thoracic Medicine, Institute of Clinical Science, University of Bergen, Haukeland University Hospital, Bergen, NorwayPeter Calverley10Division of Infection and Immunity Clinical Sciences Centre, University Hospital Aintree, Liverpool, United KingdomHarvey Coxson11Department of Radiology, Vancouver General Hospital, University of British Columbia, Vancover, CanadaCourtney Crim4GlaxoSmithKline, Research Triangle Park, North Carolina,Lisa Edwards4GlaxoSmithKline, Research Triangle Park, North Carolina,David Lomas12University of Cambridge, Cambridge Institute for Medical Research, Department of Medicine, Cambridge, United KingdomWilliam MacNee13MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United KingdomStephan Rennard14Department of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha,Julie Yates4GlaxoSmithKline, Research Triangle Park, North Carolina,Emiel Wouters1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, Netherlands15Department of Respiratory Medicine, Maastricht University Medical Centre+, Maastricht, NetherlandsMartijn Spruit1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, Netherlands
- Characteristics and outcomes of GOLD C and D COPD patientsBy Hana Müllerová, MeiLan Han, Richard Baxter and Kourtney DavisHana Müllerová1Respiratory Epidemiology, GlaxoSmithKline RD, Uxbridge, Middlesex, United KingdomMeiLan Han2Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI,Richard Baxter1Respiratory Epidemiology, GlaxoSmithKline RD, Uxbridge, Middlesex, United KingdomKourtney Davis1Respiratory Epidemiology, GlaxoSmithKline RD, Uxbridge, Middlesex, United Kingdom
- Clinical and prognostic heterogeneity of C and D GOLD groupsBy Alvar Agustí, Stephen Rennard, Lisa D. Edwards, William MacNee, Emiel Wouters, Bruce Miller, Ruth Tal-Singer, Hana Mullerova and Bartolomé CelliAlvar Agustí1Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona and CIBER Enfermedades Respiratorias (CIBERES), Barcelona, SpainStephen Rennard2Dept of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, NE, USALisa D. Edwards3Clinical Statistics, GlaxoSmithKline R&D, Research Triangle Park, NC, USAWilliam MacNee4ELEGI Labs, University of Edinburgh, Edinburgh, UKEmiel Wouters5Dept of Respiratory Medicine, Maastricht University Medical Center, Maastricht, The NetherlandsBruce Miller6Respiratory Therapy Area Unit, GlaxoSmithKline R&D, King of Prussia, PA, USARuth Tal-Singer6Respiratory Therapy Area Unit, GlaxoSmithKline R&D, King of Prussia, PA, USAHana Mullerova7Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, EnglandBartolomé Celli8Dept of Respiratory Medicine, Brigham and Women's Hospital, Boston, MA, USA
- Health status predicts long-term outcomes in patients with chronic obstructive pulmonary disease (COPD): Pooled analysis of patient-level data from the COPD biomarker qualification consortium databaseBy Hana Müllerová, Heather Gelhorn, Hilary Wilson, Victoria Benson, Niklas Karlsson, Shailendra Menjoge, Debora Merrill, Stephen Rennard, Ruth Tal-Singer, Margaret Tabberer and Paul JonesHana Müllerová1Respiratory Epidemiology, GSK, Uxbridge, United KingdomHeather Gelhorn2Statistics, Evidera, Bethesda, MD United StatesHilary Wilson2Statistics, Evidera, Bethesda, MD United StatesVictoria Benson1Respiratory Epidemiology, GSK, Uxbridge, United KingdomNiklas Karlsson3Department, AstraZeneca R&D, Mölndal, SwedenShailendra Menjoge4Biometrics and Data Management, Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, CT United StatesDebora Merrill5COPD Biomarkers Qualification Consortium, COPD Foundation, Washington, DC United StatesStephen Rennard6Division of Pulmonary, Critical Care, Sleep and Allergy, Nebrasca Medical Centre, Omaha, NE United StatesRuth Tal-Singer7COPD Clinical Discovery, GSK, King of Prussia, PA United StatesMargaret Tabberer8Value Evidence&Outcomes, GSK, Uxbridge, United KingdomPaul Jones9Institute for Infection and Immunity, St. George's University of London, London, United Kingdom
- LATE-BREAKING ABSTRACT: No relationship between cardiovascular morbidity and moderate-to-severe exacerbation rates in COPD patients in primary careBy Paul Jones, Jadwiga Wedzicha, Alvar Agusti, Marc Decramer, Alice Raillard, Hana Müllerová, Chang-Qing Zhu and Lukasz AdamekPaul Jones1Institute for Infection and Immunity, St. George's University of London, London, United KingdomJadwiga Wedzicha2National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, United KingdomAlvar Agusti3Thorax Institute, IDIBAPS, Universitat de Barcelona, Barcelona, SpainMarc Decramer4Respiratory Division, University Hospital Leuven, Leuver, BelgiumAlice Raillard5Direction Excellence Medicale Opérationnelle, GSK France, Paris, FranceHana Müllerová6Epidemiology, GSK R&D, Uxbridge, United KingdomChang-Qing Zhu7Clinical Statistics, GSK R&D, Uxbridge, United KingdomLukasz Adamek8Global Franchise Respiratory, GSK, Uxbridge, United Kingdom
- Gastro-oesophageal reflux disease and exacerbations of COPD in a cohort of 2,135 COPD patientsBy Victoria Benson, Hana Müllerová, Jørgen Vestbo, Jadwiga Wedzicha, Anant Patel and John HurstVictoria Benson1Respiratory Epidemiology, GSK R&D, Uxbridge, United KingdomHana Müllerová1Respiratory Epidemiology, GSK R&D, Uxbridge, United KingdomJørgen Vestbo2Department of Respiratory Medicine, Gentofte University Hospital, University of Copenhagen, Copenhagen, Denmark3Respiratory and Allergy Research Group, Manchester Academic Health Science Centre, University Hospital South Manchester NHS Foundation Trust, Manchester, United KingdomJadwiga Wedzicha4Airway Disease Section, National Heart and Lung Institute, Imperial College, London, United KingdomAnant Patel5UCL Respiratory Medicine, University College London, Royal Free Campus, Rowland Hill Street, London, United KingdomJohn Hurst5UCL Respiratory Medicine, University College London, Royal Free Campus, Rowland Hill Street, London, United Kingdom
- Validation of the recording of acute exacerbations of COPD in the clinical practice research datalink: Phase 1 resultsBy Kieran Rothnie, Hana Mullerova, John Hurst, Liam Smeeth, Kourtney Davis, Sara Thomas and Jennifer QuintKieran Rothnie1Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United KingdomHana Mullerova2Respiratory Epidemiology, GlaxoSmithKline R&D, Uxbridge, United KingdomJohn Hurst3UCL Respiratory Medicine, University College London Medical School, London, United KingdomLiam Smeeth1Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United KingdomKourtney Davis2Respiratory Epidemiology, GlaxoSmithKline R&D, Uxbridge, United KingdomSara Thomas1Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United KingdomJennifer Quint1Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, and a companion volume of self-assessment questions is available. In 2015, the first ERS Practical Handbook, on Noninvasive Ventilation, was added to the series
